BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 38066907)

  • 21. Bispecific Antibodies in the Treatment of Multiple Myeloma.
    Zhou X; Xiao X; Kortuem KM; Einsele H
    Hematol Oncol Clin North Am; 2024 Apr; 38(2):361-381. PubMed ID: 38199897
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patient selection for chimeric antigen receptor (CAR) T-cell therapy for aggressive B-cell non-Hodgkin lymphomas.
    Johnson PC; Abramson JS
    Leuk Lymphoma; 2020 Nov; 61(11):2561-2567. PubMed ID: 32611216
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Unscheduled health care interactions in patients with multiple myeloma receiving T-cell redirection therapies.
    Howard AJ; Concepcion I; Wang AX; Hamadeh IS; Hultcrantz M; Mailankody S; Tan C; Korde N; Lesokhin AM; Hassoun H; Shah UA; Maclachlan KH; Rajeeve S; Landau HJ; Scordo M; Shah GL; Lahoud OB; Chung DJ; Giralt S; Usmani SZ; Firestone RS
    Blood Adv; 2024 Jun; 8(12):3246-3253. PubMed ID: 38621239
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CAR-T in B-Cell Lymphomas: The Past, Present, and Future.
    Al-Juhaishi T; Ahmed S
    Clin Lymphoma Myeloma Leuk; 2022 Apr; 22(4):e261-e268. PubMed ID: 34782260
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of relapsed or refractory large B-cell lymphoma in patients ineligible for CAR-T cell therapy.
    Perrone S; Lopedote P; Levis M; Di Rocco A; Smith SD
    Expert Rev Hematol; 2022 Mar; 15(3):215-232. PubMed ID: 35184664
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CAR T-Cell Therapy for Relapsed/Refractory Aggressive Large B-Cell Lymphoma.
    Gideon J
    Clin J Oncol Nurs; 2022 Nov; 26(6):597-601. PubMed ID: 36413724
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characteristics and treatment patterns of relapsed/refractory diffuse large B-cell lymphoma in patients receiving ≥3 therapy lines in post-CAR-T era.
    Xie J; Wu A; Liao L; Nastoupil LJ; Du EX; Noman A; Chen L
    Curr Med Res Opin; 2021 Oct; 37(10):1789-1798. PubMed ID: 34344238
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Experiences with Glofitamab Administration following CAR T Therapy in Patients with Relapsed Mantle Cell Lymphoma.
    Heini AD; Bacher U; Porret N; Wiedemann G; Legros M; Stalder Zeerleder D; Seipel K; Novak U; Daskalakis M; Pabst T
    Cells; 2022 Sep; 11(17):. PubMed ID: 36078155
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabolic parameters predict survival and toxicity in chimeric antigen receptor T-cell therapy-treated relapsed/refractory large B-cell lymphoma.
    Ababneh HS; Ng AK; Abramson JS; Soumerai JD; Takvorian RW; Frigault MJ; Patel CG
    Hematol Oncol; 2024 Jan; 42(1):e3231. PubMed ID: 37795759
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcome after chimeric antigen receptor (CAR) T-cell therapy failure in large B-cell lymphomas.
    Dodero A; Bramanti S; Di Trani M; Pennisi M; Ljevar S; Chiappella A; Massimo M; Guidetti A; Corrado F; Nierychlewska PM; Di Rocco A; Lorenzini D; Daoud R; De Philippis C; Santoro A; Carlo-Stella C; Corradini P
    Br J Haematol; 2024 Jan; 204(1):151-159. PubMed ID: 37690811
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
    Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
    Front Immunol; 2020; 11():564099. PubMed ID: 33329526
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Allogeneic Stem Cell Transplantation and Chimeric Antigen Receptor (CAR) T-Cell Therapy for the Treatment of Non-Hodgkin Lymphoma.
    Hunter BD; Chen YB; Jacobson CA
    Hematol Oncol Clin North Am; 2019 Aug; 33(4):687-705. PubMed ID: 31229163
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chimeric antigen receptor T-cells, bispecific antibodies, and antibody-drug conjugates for multiple myeloma: An update.
    Lakshman A; Kumar SK
    Am J Hematol; 2022 Jan; 97(1):99-118. PubMed ID: 34661922
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Current and future perspectives on CAR-T cell therapy to adult malignant lymphoma].
    Shimoyama T
    Rinsho Ketsueki; 2023; 64(9):1192-1202. PubMed ID: 37899200
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma: Practical Implications for the Community Oncologist.
    Jacobson CA; Farooq U; Ghobadi A
    Oncologist; 2020 Jan; 25(1):e138-e146. PubMed ID: 31585984
    [TBL] [Abstract][Full Text] [Related]  

  • 36. How I treat refractory/relapsed diffuse large B-cell lymphomas with CD19-directed chimeric antigen receptor T cells.
    Nagler A; Perriello VM; Falini L; Falini B
    Br J Haematol; 2023 May; 201(3):396-410. PubMed ID: 36916189
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
    Abramson JS; Palomba ML; Gordon LI; Lunning MA; Wang M; Arnason J; Mehta A; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Albertson TM; Garcia J; Kostic A; Mallaney M; Ogasawara K; Newhall K; Kim Y; Li D; Siddiqi T
    Lancet; 2020 Sep; 396(10254):839-852. PubMed ID: 32888407
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic value of baseline and early response FDG-PET/CT in patients with refractory and relapsed aggressive B-cell lymphoma undergoing CAR-T cell therapy.
    Georgi TW; Kurch L; Franke GN; Jentzsch M; Schwind S; Perez-Fernandez C; Petermann N; Merz M; Metzeler K; Borte G; Hoffmann S; Herling M; Denecke T; Kluge R; Sabri O; Platzbecker U; Vučinić V
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):6131-6138. PubMed ID: 36662305
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Blinatumomab as salvage therapy in patients with relapsed/refractory B-ALL who have failed/progressed after anti-CD19-CAR T therapy.
    Qi Y; Liu H; Li X; Shi Y; Mu J; Li J; Wang Y; Deng Q
    Ann Med; 2023 Dec; 55(1):2230888. PubMed ID: 37417690
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcomes of CD19 Chimeric Antigen Receptor T Cell Therapy in Patients with Gastrointestinal Tract Involvement of Large B Cell Lymphoma.
    Cortes-Bullich A; Perez A; Bachmeier C; Mhaskar R; Chavez JC; Shah B; Nishihori T; Khimani F; Lazaryan A; Davila ML; Locke FL; Jain MD
    Transplant Cell Ther; 2021 Sep; 27(9):768.e1-768.e6. PubMed ID: 34077811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.